Knockdown of IncRNA TDRG1 Inhibits Tumorigenesis in Endometrial Carcinoma Through the PI3K/AKT/mTOR Pathway

Background and objective: Endometrial carcinoma (EC) is one of the most frequently diagnosed malignancies in females. Dysregulation of IncRNA TDRG1 has been widely documented in several cancers, including EC. However, the mechanism of this IncRNA involving in EC progression remains to be further elucidated.

Materials and methods: The enrichment levels of TDRG1 in EC tissues and cell lines were examined by RT-qPCR. Flow cytometry, cell counting kit-8 (CCK-8), transwell, and Western blot assays were conducted to assess whether TDRG1 knockdown could affect cell cycle arrest, proliferation, migration, invasion, and apoptosis of EC cells. The phosphorylation levels of mTOR, AKT and PI3K that associated with PI3K/Akt/mTOR pathway were determined by Western blot assay.

Results: TDRG1 expression was markedly upregulated in EC tissues and cell lines. Knockdown of TDRG1 significantly induced cell cycle arrest and apoptosis, inhibited cell proliferation, restrained the invasion and migration abilities in EC cells. Moreover, TDRG1 silencing decreased the protein levels of p-AKT, p-PI3K, and p-mTOR of EC cells.

Conclusion: Our data underlined the implication of TDRG1 in EC progression, proposing that targeting TDRG1 might be a potential therapeutic avenue in EC.

Keywords: endometrial carcinoma, TDRG1, PI3K/AKT/mTOR pathway

Introduction

Endometrial carcinoma (EC) is a common malignancy occurring in the female genital system with almost 63,230 new cases and 11,350 deaths in the United States just in 2018. In recent years, this disease exhibits a trend in younger women attributed to the increased obesity and reduced physical activity. Surgery is considered as the mainstay for EC treatment, with radiotherapy and chemotherapy having established places in the adjuvant treatment setting. Nevertheless, these treatments fail to be effective for those patients with distant metastases and advanced TNM stage. Over the past decades, clinicopathological, epidemiological and genetic studies have enhanced our understanding of EC. Previous studies have highlighted a series of genes, including PTEN, COX-2, survivin, and PIK3CA that are linked with the occurrence and development of EC. However, the clinical application of these markers remains controversial. Thus, identification of novel therapeutic targets and further clarification of the potential molecular mechanisms involving in the emergence and progression of EC are of great significance for EC treatment.
Recent data obtained from the ENCODE project revealed that a large proportion of the human genome could be transcribed into non-coding RNAs (ncRNAs).\textsuperscript{11,12} LncRNAs are a group of ncRNA transcripts with a length greater than 200 nucleotides, have emerged as essential regulators in diverse cellular processes, including cell cycle, proliferation, differentiation, apoptosis, invasion, and migration.\textsuperscript{13} Dysregulation of lncRNAs has been reported in a vast range of human cancers.\textsuperscript{14} In addition, the involvement of some lncRNAs in EC tumorigenesis has also been confirmed. For instance, the elevated of lncRNA H19 actively contributes to tumorigenesis in EC via regulation of epithelial-mesenchymal transition (EMT).\textsuperscript{15} LncRNA CCAT2 exerts a critical regulatory function in EC metastasis and cell growth.\textsuperscript{16} LncRNA GAG5 and FER1L4 act as a tumor suppressor by enhancing the expression of PTEN in EC.\textsuperscript{17,18}

Human testis developmental related gene 1 (TDRG1) is a novel human testis-specific lncRNA that is differentially expressed in testicular germ cell tumor tissue and normal testicular tissue.\textsuperscript{19} Abnormal expression of TDRG1 may be associated with the malignant processes of diverse cancers, including seminoma,\textsuperscript{20} epithelial ovarian carcinoma,\textsuperscript{21} and EC.\textsuperscript{22} However, the underlying mechanism of TDRG1 involving in EC progression remains to be further investigated.

In this study, elevated abundances of TDRG1 were observed in EC tissues and cell lines. Knockdown of TDRG1 by transient transfection with si-TDRG1 induced cell cycle arrest and apoptosis, while hampered cell proliferation, migration, and invasion. Furthermore, we also confirmed that lncRNA TDRG1 functioned as an activator of the PI3K/Akt/mTOR signaling pathway.

**Materials and Methods**

**Reagents**

Human endometrial epithelial cell (hEEC) was purchased from the American Type Culture Collection (ATCC, Rockefeller, MD, USA). EC cell lines (HEC-1A and Ishikawa) were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China) and Cell Resource Center of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China), respectively. RPMI-1640 medium, McCoy’s medium, minimum Eagle’s medium (MEM) and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA). Penicillin-streptomycin, cell counting kit-8 (CCK-8), and BCA protein quantification kit were obtained from Solarbio (Beijing, China). Lipofectamine 2000, TRIZol® reagent, M-MLV Reverse Transcriptase Kit, SYBR Green PCR Master Mix, PCR primers, siRNA targeting TDRG1 (si-TDRG1), siRNA targeting control (si-NC), TDRG1 expressing plasmid (TDRG1) and its negative control (vector) were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Cell Cycle and Apoptosis Analysis Kit and Annexin V-FITC Apoptosis Detection Kit were bought from Beyotime (Shanghai, China). Polyvinylidene fluoride (PVDF) membrane was obtained from Millipore (Billerica, MA, USA). Specific antibodies against proliferating cell nuclear antigen (PCNA), MMP-9, MMP-2, Bel-2, Bax, cleaved caspase 3, p-mTOR, mTOR, p-AKT, AKT, p-PI3K, PI3K, β-actin, and HRP-conjugated secondary antibody were obtained from Abcam (Cambridge, MA, USA). Enhanced chemiluminescence reagent (ECL) was purchased from GE Healthcare (Giles, UK). Matrigel was provided by BD Biosciences (San Jose, CA, USA).

**Clinical Specimens**

EC tissues (n=35) and normal tissues (n=15) were collected from patients who underwent surgical resection at the Affiliated Hospital of Weifang Medical University between Feb 2015 and Oct 2017, and were affirmed by histopathological diagnosis. No patient received preoperative treatment, including chemotherapy and radiotherapy. After surgery, these samples were immediately frozen and stored at −80°C until further use. This study was performed with the approval of the Research Ethics Committee of the Affiliated Hospital of Weifang Medical University, and written informed consent was obtained from all participants.

**Cell Culture and Transfection**

hEEC cells were cultured in RPMI-1640 medium, HEC-1A cells were cultured in McCoy’s medium, and Ishikawa cells were cultured in MEM. All the medium contained 10% FBS and 1% penicillin-streptomycin, and all cells were cultured at 37°C with 5% CO\textsubscript{2} incubator. The medium was changed every 48 h until cells reached the confluence of 80–85%. Then, Lipofectamine 2000 was used to transfected si-TDRG1, TDRG1, or their negative controls into cells.

Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA from EC tissues and cell lines were extracted using TRIZol® reagent. Then, M-MLV Reverse Transcriptase Kit was applied for RNA reverse transcription on the basis of the manufacturer’s instructions. For TDRG1 expression, qPCR was conducted using SYBR Green PCR Master Mix on Applied Biosystems 7500 real-time PCR system. Primer sequences for TDRG1 were 5’-GAAGAGGAGGGAGGC-3’ and 5’-GAAGAGGAGGGAGGC-3’.
AGTCT-3' (forward) and 5'-GGGAACCTAGACCTGGGA AG-3' (reverse); GAPDH were 5'-GGAGCGAGATCCCTCAAAAT-3' (forward) and 5'-GGCTGTTGTCATACTTCTCATGGG-3' (reverse). The average value from three independent experiments was used to calculate the relative expression of TDRG1 using 2^{-ΔΔCt} method, and GAPDH was used as an internal control.

Cell Cycle Analysis
Cell cycle assay was performed by PI single staining method using Cell Cycle and Apoptosis Analysis Kit. Briefly, after transfecting with si-TDRG1 or si-NC for 48 h, Ishikawa and HEC-1A cells were washed with PBS, centrifuged at 1000 rpm for 5 min, and fixed with 75% cold ethanol at 4°C overnight. Afterward, cells were re-suspended with cold PBS and stained with cell cycle staining solution containing PI and RNase A at 37°C for 30 min. The percentage of cells in each cell cycle phase was analyzed on a flow cytometer using Cell Quest Pro software.

Cell Proliferation Analysis
Cell viability was determined using CCK-8 according to the manufacturer’s instructions. Generally, Ishikawa and HEC-1A cells transfected si-NC or si-TDRG1 were seeded into 96-well plates at a density of 3000 cells/well. At different points after transfection (0 h, 24 h, 48 h, and 72 h), 10 μL CCK-8 solution was added into each well for 2 h at 37°C, and the absorbance at 450 nm was measured by a microplate reader.

Western Blot
Total proteins were extracted using RIPA buffer and quantified using the BCA protein quantification kit. Then, an equal amount of proteins were denatured at 98°C for 5 min, separated by SDS-PAGE and transferred onto PVDF membranes. After blocked with skim milk for 2 h, the membranes were incubated with specific antibodies overnight at 4°C, with β-actin as an internal reference. Then, the membranes were washed with TBST buffer and exposed to horseradish peroxidase (HRP)-conjugated secondary antibody for 2 h. Protein bands were detected using ECL reagent and quantified by Image J software.

Migration and Invasion Assays
Cell migration and invasion assays were implemented using transwell chambers with 8.0 µm pore-size polycarbonate membranes. For migration assay, 1×10^5 cells suspended in serum-free medium were loaded onto the upper chambers, and the lower chambers were filled with 500 μL complete medium containing 10% FBS. After cultured for 16 h, non-migratory cells on the top surface of the membranes were removed using cotton swabs. The cells of the lower chambers surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violets. Next, the number of migrated cells was recorded for randomly selected five fields of view. For invasion assay, the upper chambers were pre-coated with 100 µL of Matrigel, and cell invasion assay was performed as described above.

Cell Apoptosis Analysis
Annexin V-FITC/PI double-staining method was applied for cell apoptosis analysis using Annexin V-FITC Apoptosis Detection Kit. In brief, collected Ishikawa and HEC-1A cells were washed with PBS and re-suspended with binding buffer. After double-stained with Annexin V and PI avoid of light for 15 min, cell apoptosis in each well was analyzed by a flow cytometer.

Statistical Analyses
SPSS 20.0 software was applied for all statistical analyses. The data from more than 3 independent experiments were displayed as the mean ± standard deviation (SD). Difference analysis between two or more groups was carried out using Student’s t-test or one-way ANOVA test. P < 0.05 was considered to be statistically significant.

Results
TDRG1 Was Upregulated in EC Tissues and Cell Lines
The expression pattern of TDRG1 in EC tissues and cell lines was determined by RT-qPCR. As shown in Figure 1A, TDRG1 was highly expressed in EC tissues (35 cases) compared to normal tissues (15 cases). Likewise, the expression of TDRG1 was markedly elevated in EC cell lines (HEC-1A and Ishikawa) compared with that in normal hEEC cells (Figure 1B). Furthermore, the relationship between TDRG1 and the clinicopathological parameters of EC patients showed that high TDRG1 expression was positively correlated with the tumor grade and stage of EC patients (P < 0.05, Table 1). These findings provided evidence that TDRG1 might play a central role in EC.
Knockdown of TDRG1 Induced Cell Cycle Arrest and Hindered Proliferation in EC Cells

To investigate the biological significance of TDRG1 in EC, loss-of-function assay was performed via knockdown of TDRG1 in Ishikawa and HEC-1A cells. The results of RT-qPCR assay showed that transfection of si-TDRG1 resulted in a significant reduction of TDRG1 expression in Ishikawa and HEC-1A cells compared to control (Figure 2A), indicating that si-TDRG1 could be used for the subsequent loss-of-function study. Flow cytometry for cell cycle assay demonstrated that TDRG1 downregulation triggered cell cycle arrest at G0/G1 in Ishikawa and HEC-1A cells (Figure 2B). CCK-8 assay revealed that si-TDRG1 significantly inhibited cell viability compared to the si-NC group (Figure 2C). In addition, Western blot assay results indicated that the protein level of PCNA was obviously reduced in Ishikawa and HEC-1A cells after si-TDRG1 transfection (Figure 2D).

Knockdown of TDRG1 Restrained Cell Migration and Invasion in EC Cells

Transwell assay revealed that the silencing of TDRG1 significantly impeded the migration and invasion abilities of Ishikawa and HEC-1A cells (Figure 3A and B). MMP-2 and MMP-9, known as key enzymes in the degradation of type IV collagen, are closely correlated with tumor invasion and metastatic potential. Western blot assay results displayed that the protein levels of MMP-9 and MMP-2 were markedly increased by the knockdown of TDRG1 in Ishikawa and HEC-1A cells (Figure 3C), which further demonstrated that TDRG1 depletion relieved the aggressive phenotype of EC cells.

The Stimulatory Effect of TDRG1 Knockdown on EC Cell Apoptosis

Flow cytometry for apoptosis assay showed that the apoptotic rate of Ishikawa and HEC-1A cells in the si-TDRG1 group was higher than that in the si-NC group (Figure 4A). Next, we also performed Western blot assay to detect the protein levels of anti-apoptotic protein Bcl-2, pro-apoptotic protein Bax, and cleaved caspase-3 in EC cells. Results showed that knockdown of TDRG1 suppressed Bcl-2

---

Table 1 The Relationship Between TDRG1 Level and the Clinicopathological Parameters of 35 EC Patients

| Clinicopathologic Parameters | Relative TDRG1 Level | P Value |
|-----------------------------|----------------------|---------|
|                            | High (%)             | Low (%)     |
| Age (years)                 |                      |           |
| ≥55                         | 11 (57.9)            | 8 (42.1)   | 0.6405  |
| <55                         | 8 (50.0)             | 8 (50.0)   |         |
| Grade                       |                      |           |
| G1+G2                       | 7 (35.0)             | 13 (65.0)  | 0.0082* |
| G3                          | 12 (80.0)            | 3 (20.0)   |         |
| Stage                       |                      |           |
| I - II                      | 9 (39.1)             | 14 (60.9)  | 0.0127* |
| III-IV                      | 10 (83.3)            | 2 (16.7)   |         |
| Lymph node metastasis       |                      |           |
| No                          | 13 (50.0)            | 13 (50.0)  | 0.387   |
| Yes                         | 6 (66.7)             | 3 (33.3)   |         |

Note: *P<0.05.
expression, while induced Bax and cleaved caspase 3 expressions compared with the control group (Figure 4B). These results indicated that TDRG1 silencing contributed to EC cell apoptosis.

**TDRG1 Activated PI3K/Akt/mTOR Signaling Pathway in EC Cells**

To investigate whether TDRG1 was involved in the progression of EC cells via regulating PI3K/AKT/mTOR signaling pathway, the levels of relevant proteins associated with this pathway were examined by Western blot assay. As shown in Figure 5A and B, TDRG1 overexpression increased the protein levels of p-mTOR, p-AKT and p-PI3K in Ishikawa and HEC-1A cells, while TDRG1 silencing decreased their levels, indicating that knockdown of TDRG1 exerted its antitumor property possibility via the blockade of PI3K/AKT/mTOR signaling pathway.

**Discussion**

LncRNAs have emerged as critical regulators in cellular behaviors and many of them are identified to be implicated in the formation and progression of human cancers. Researchers...
have found that ectopic expressions of lncRNAs, such as H19, MALAT1, and HOTAIR, are pervasively overexpressed in most solid cancers and correlate with tumorigenesis and development.\textsuperscript{25–27} The low-expressed pattern of lncRNA

\textbf{Figure 3} Knockdown of TDRG1 prevented migration and invasion in EC cells. Ishikawa and HEC-1A cells were transfected with si-NC or si-TDRG1 for 48 h. Cell migration and invasion abilities were assessed by Transwell assay (A and B), and the protein levels of MMP-9 and MMP-2 were measured by Western blot assay (C). **P < 0.01, ***P < 0.001.
GAS5 heightens the proliferative capacity of tumor cells and signifies a poorer prognosis. Cell apoptosis usually involves the activation, expression and regulation of a series of genes, including the decrease of Bcl-2 expression and the increase of Bax and caspase-3 expression. Lnc-SOX6-1, HOST2 and lnc-Sox5 have been shown to inhibit apoptosis of cells in many diseases and thus promote disease progression, including pediatric acute myeloid leukemia, osteosarcoma and tongue carcinogenesis. Besides, some lncRNAs are reported to be greatly implicated in the tumorigenesis of EC by serving as tumor suppressors or oncogenes, such as FER1L4, BANCR, and TUG1. However, the clinical application of these biomarkers remains controversial. Thereby, identifying a potential biomarker that associated with the carcinogenesis has vital practical significance for EC diagnosis and treatment.

As a newly characterized human testis-specific gene, lncRNA TDRG1 has the potential to encode a 100-amino acid protein that lacks characterized protein domains. Early study indicates that TDRG1 contributes to the occurrence and development of testicular seminoma. Additionally, elevated expression of TDRG1 is identified as an oncogene in epithelial ovarian carcinoma and positively correlates with the poor prognosis and malignant progression. The present study revealed that TDRG1 expression was markedly higher in EC

![Figure 4](https://example.com/final_fig4.png)  
**Figure 4** Knockdown of TDRG1 induced EC cell apoptosis. Ishikawa and HEC-1A cells were transfected with si-NC or si-TDRG1. Then, cell apoptotic rate was detected by flow cytometry using Annexin V-FITC/PI double-staining method (A), protein levels of Bcl-2, Bax and cleaved caspase 3 were examined by Western blot assay (B). **P < 0.01, ***P < 0.001.
tissues and cell lines than that in normal tissues and hEEC cells, indicating the possible involvement of this lncRNA in EC progression. Next, TDRG1 was knocked down by the transfection of si-TDRG1 into EC cells, followed by a series of functional researches by flow cytometry, CCK-8, transwell, and Western blot analyses. We observed that knockdown of TDRG1 increased the distribution of G0/G1, and impeded cell proliferation in Ishikawa and HEC-1A. Furthermore, the migration and invasion abilities were suppressed and apoptosis was enhanced in EC cells after TDRG1 knockdown. Our findings were fully consistent with the previous study reported by Chen et al, who highlighted the promotive effects of TDRG1 on EC cell tumorigenicity and tumor growth.}{.5}{.5}

PI3K/AKT/mTOR signaling pathway regulates several normal cellular processes, including cell survival, proliferation, growth, and death. PI3K is a heterodimer that is composed of an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic subunit (p110). Activated PI3K has the ability to recruit AKT to the plasma membrane, leading to the phosphorylation of various proteins, including mTOR. mTOR functions as a catalytic subunit of mTORC1 complex, the activation of which affects cell proliferation and survival by repressing autophagy. Until now, a large amount of evidence has confirmed the critical role of PI3K/AKT/mTOR signaling pathway in various tumorigenesis. Aberrant expression or mutation of many components in this pathway are associated
with the malignant processes of several types of human cancers, such as cervical, ovarian cancer, colorectal cancer, and breast cancer. Also, activated PI3K/AKT/mTOR signaling is associated with the aggressive progression and poor prognosis in EC. Thus, identifying a novel biomarker that connected with PI3K/AKT/mTOR pathway is of great significance for cancer therapy.

Early research by Li et al showed that abnormally elevated lncRNA UCA1 played a pivotal role in the tumorigenesis of gastric cancer through the PI3K/AKT/mTOR pathway. Yang et al stated that lncRNA SNHG7 was associated with the poor prognosis and triggered colorectal cancer progression via activating PI3K/AKT/mTOR pathway. In our study, we observed that the protein levels of p-mTOR, p-AKT and p-PI3K were decreased in EC cells after TDRG1 knockdown. Thus, we proposed the conclusion that TDRG1 contributed to the progression of EC by the activation of PI3K/AKT/mTOR signaling pathway.

Lymph node involvement is one of the most important adverse prognostic factors of EC, which seriously affects the survival rate of patients. Preoperative risk assessment of lymph node metastasis can effectively predict the incidence of lymph node metastasis after surgery in order to develop the best treatment for patients. Nevertheless, once lymph node metastasis occurs in postoperative patients, the mortality rate will be very high. Therefore, the proposal of EC biomarkers can also provide certain clinical diagnostic value for the prognosis of EC patients.

As a regulator of cancer progression, the role of many lncRNAs has been confirmed. This study explored the role of TDRG1 in EC tumorigenesis, confirmed its existence as a cancer-promoting factor of EC, emphasized the important role of TDRG1 in EC progression, and added a new reference for the study of TDRG1. However, there are some deficiencies in this study. We only explore the function of TDRG1 in EC, but its mechanism is not well understood. In addition, the experimental results in this study have only been confirmed at the cellular level, and there may be some limitations. Therefore, further experiments may be around to explore the mechanism of TDRG1 in EC and further validation of our experimental results in vivo.

In conclusion, our data indicated that knockdown of TDRG1 restrained EC development via regulating the PI3K/AKT/mTOR signaling pathway. These findings contributed to a better understanding on the regulatory mechanism of TDRG1 in EC progression, which might provide a novel therapeutic avenue for EC treatment.

Funding
This work was financially supported by the Project of Medical Science and Technology Development Plan in Shandong Province (Grant No. 2017WS242).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca a Cancer J Clin. 2018;68(1):11. doi:10.3322/caac.21442
2. Friberg E, Mantzoros CS, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2136–2140. doi:10.1158/1055-9965.EPI-06-0465
3. Koutoukidis DA, Knobf MT, Lanceley A. Obesity, diet, physical activity, and health-related quality of life in endometrial cancer survivors. Nutr Rev. 2015;73(6):399–408. doi:10.1093/nutrit/nuu063
4. Kupets R, Le T, Le T, et al. The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can. 2013;35(4):375–376. doi:10.1016/S1701-2163(15)30968-3
5. Humber C, Tierney J, Symonds P, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2005(5):CD003915.
6. Salvesen HB, Macdonald N, Ryan A, et al. PTENmethylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2015;91(1):22–26. doi:10.1002/ijc.26051
7. Erkanli S, Bolat F, Kayasaleck F, et al. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 2007;104(2):320–325. doi:10.1016/j.ygyno.2006.08.044
8. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37(11):1465–1472. doi:10.1016/j.humpath.2006.05.007
9. Velasco A, Bussaglia E, Dolcet X, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37(11):1465–1472. doi:10.1016/j.humpath.2006.05.007
10. Kun-Tu Y, Ming-Yu Y, Ta-Chih L, et al. Abnormal expression of PER1 in endometrial carcinoma. J Pathol. 2005;206(1):111–120. doi:10.1002/path.1756
11. Salem M. Genome-wide discovery of long non-coding RNAs in Rainbow Trout and their potential roles in muscle growth and quality. Plant Animal Genome. 2015;11:e014890.
12. Sarah D, Davis CA, Angelika M, et al. Landscape of transcription in human cells. Nature. 2012;489:101–108.
13. Petri A, Dybkær K, Bagsted M, et al. Long noncoding RNA expression during human B-cell development. PLoS One. 2015;10(9): e0138236. doi:10.1371/journal.pone.0138236
14. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(11):1097–1109. doi:10.1016/j.bbadis.2014.08.012
15. Zhao L, Li Z, Chen W, et al. H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett. 2017;13(1):363. doi:10.3892/ol.2016.5389
16. Xie P, Cao H, Li Y, et al. Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b. Cancer Biomarkers. 2017;21:1–11.
17. Guo C, Song WQ, Sun P, et al. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci. 2015;22(1):100. doi:10.1186/s12929-015-0213-4

OncoTargets and Therapy 2019:12
20. Wang Y, Gan Y, Tan Z, et al. TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway. Oncotargets Ther. 2016;9(1):409.

21. Chen S, Wang LL, Sun KX, et al. The role of the long non-coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miR-93/Rhoc pathway. Mol Carcinog. 2018;57(2):225. doi:10.1002/mc.22749.

22. Chen S, Wang LL, Sun KX, et al. LncRNA TDRG1 enhances tumorigenicity in endometrial cancer by binding and targeting VEGF-A protein. Biochim Biophys Acta. 2018;1864(9):S925443918302175. doi:10.1016/j.bbadis.2018.06.013.

23. Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26(5):3579–3583.

24. Zhou R, Xu L, Ye M, et al. Formononetin inhibits migration and invasion of MDA-MB-231 and MCT breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 2014;46(11):753–760. doi:10.1055/s-0035-15000025.

25. Raveh E, Matouk IJ, Gilon M, et al. The H19 long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory. Mol Cancer. 2015;14(1):184. doi:10.1186/s12943-015-0458-2.

26. Gutschner T, Hämmerle M, Diederichs S. MALAT1 — a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791–801. doi:10.1007/s00109-013-1028-y.

27. Wu Y, Zhang L, Wang Y, et al. Long non-coding RNA HOTAIR promotes tongue carcinogenesis. Biochemistry (Mosc). 2017;82(4):438–445. doi:10.1134/S0006279717040046.

28. Wang D, Wang D, Wang N, et al. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem. 2016;40(3–4):644. doi:10.1159/000452577.

29. Liu L, Chen X, Zhang Y, et al. Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. J Oncotarget. 2017;8(19):31386–31394. doi:10.18632/oncotarget.15607.

30. Xianzhen J, Dongjie L, Jianyu Y, et al. Characterization of a novel human testis-specific gene: testsis developmental related gene 1 (TDRG1). Tohoku J Exp Med. 2011;225(4):311–318. doi:10.1620/tjem.225.311.

31. Guan X, Wen X, Xiao J, An X, Yu J, Guo Y. Lnc-SOX6-1 upregulates MMP2 and MMP1 via ERK/MAPK signaling pathway. Mol Cancer Res. 2018;16(9):1234–1241. doi:10.1158/1535-7163.MCR-17-0405.

32. Qiao O, Li H. LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun. 2016;478(2):507–512. doi:10.1016/j.bbrc.2016.06.160.

33. Wu Y, Zhang L, Wang J, et al. HuR stabilizes lnc-Sox5 mRNA to promote tongue carcinogenesis. Biochemistry (Mosc). 2017;82(4):438–445. doi:10.1134/S0006279717040046.

34. Sun et al. LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun. 2016;478(2):507–512. doi:10.1016/j.bbrc.2016.06.160.

35. Zhang L, Ye S, Wang J, et al. The phosphatidylinositol 3-Kinase AKT pathway: a therapeutic target in endometrial cancer. Tumor Biol. 2013;34(10):5931–5938. doi:10.1007/s13277-013-2292-9.

36. Xianzhen J, Dongjie L, Jianyu Y, et al. Characterization of a novel human testis-specific gene: testsis developmental related gene 1 (TDRG1). Tohoku J Exp Med. 2011;225(4):311–318. doi:10.1620/tjem.225.311.

37. Jiri P. Targets for cancer therapy in the PI3K/AKT/mTOR pathway. JE x pM e d. 2013.12.004.

38. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834–4839. doi:10.1073/pnas.0806514106.

39. Cignini P, Vitale SG, Lagana AS, Biondi A, La Rosa VL, Cutillo G. The phosphatidylinositol 3-Kinase AKT pathway in colorectal cancer progression. FEBS Lett. 2013;587(6):1247–1253. doi:10.1016/j.febslet.2013.02.037.

40. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in tumors of advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011;10(3):558–565. doi:10.1158/1055-7586.MCT-10-0994.

41. Kang S, Nam JH, Bae DS, et al. Preoperative assessment of lymph node metastasis in endometrial cancer: a Korean Gynecologic Oncology Group study. Cancer. 2017;123(2):263–272. doi:10.1002/cncr.30349.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

Onco Targets and Therapy
Publish your work in this journal

Onco Targets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.